Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans
- PMID: 12544511
- DOI: 10.1097/00008571-200301000-00006
Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans
Abstract
CYP2D6 is involved in the O-demethylation metabolic pathway of venlafaxine in humans. In this study, we investigated whether this isozyme is stereoselective. Plasma samples from seven CYP2D6 extensive metabolizers (EMs) and five CYP2D6 poor metabolizers (PMs), collected during a period without and with coadministration of quinidine, were analysed. Subjects were administered venlafaxine hydrochloride 18.75 mg orally every 12 h for 48 h on two occasions (1 week apart); once alone and once during the concomitant administration of quinidine sulphate every 12 h. Blood and urine samples were collected under steady-state conditions over one dosing interval (12 h). The present results show that, although CYP2D6 catalyses the O-demethylation of both enantiomers of venlafaxine, it displays a marked stereoselectivity towards the (R)-enantiomer. The oral clearance of (R)-venlafaxine was found to be nine-fold higher in EMs compared to PMs [median (range) 173 (29-611) l/h versus 20 (16-24) l/h, P < 0.005], while it was two-fold higher for (S)-venlafaxine [73 (32-130) l/h versus 37 (21-44) l/h, P < 0.05]. In EMs, quinidine decreased (R)- and (S)-venlafaxine oral clearance by 12-fold ( 0.05) and four-fold ( 0.05), respectively. In contrast, quinidine did not have any effects on renal clearance of (R)-venlafaxine [4 (2-10) l/h for venlafaxine alone versus 5 (0.6-7) l/h for venlafaxine + quinidine] and of (S)-venlafaxine [4 (1-7) l/h for venlafaxine alone versus 3 (0.4-6) l/h for venlafaxine + quinidine]. The coadministration of quinidine to EMs resulted in an almost complete inhibition of the partial metabolic clearance of (R)-venlafaxine to O-demethylated metabolites [127 (10-493) l/h down to 1 (0.1-3) l/h, 0.05], while a seven-fold reduction was measured for (S)-venlafaxine [47 (14-94) l/h versus 7 (1-19) l/h, 0.05]. In PMs, coadministration of quinidine did not significantly change oral clearance and partial metabolic clearance of (R)- and (S)-venlafaxine to its various metabolites. In contrast, data obtained on the partial metabolic clearance of (R)- and (S)-venlafaxine to N-demethylated metabolites, a reaction which is mediated by CYP3A4, suggest a lack of stereoselectivity of this enzyme.
Similar articles
-
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.Pharmacogenetics. 1999 Aug;9(4):435-43. Pharmacogenetics. 1999. PMID: 10780263 Clinical Trial.
-
Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.J Clin Psychopharmacol. 2001 Apr;21(2):175-84. doi: 10.1097/00004714-200104000-00009. J Clin Psychopharmacol. 2001. PMID: 11270914
-
Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.Clin Drug Investig. 2011;31(3):155-67. doi: 10.2165/11586630-000000000-00000. Clin Drug Investig. 2011. PMID: 21288052 Clinical Trial.
-
PharmGKB summary: venlafaxine pathway.Pharmacogenet Genomics. 2014 Jan;24(1):62-72. doi: 10.1097/FPC.0000000000000003. Pharmacogenet Genomics. 2014. PMID: 24128936 Free PMC article. Review. No abstract available.
-
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.Clin Pharmacokinet. 2009;48(11):689-723. doi: 10.2165/11318030-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19817501 Review.
Cited by
-
Physiologically Based Pharmacokinetic Model of CYP2D6 Associated Interaction Between Venlafaxine and Strong Inhibitor Bupropion-The Influence of Age-Relevant Changes and Inhibitory Dose to Classify Therapeutical Success and Harm.Pharmaceutics. 2025 Jan 31;17(2):179. doi: 10.3390/pharmaceutics17020179. Pharmaceutics. 2025. PMID: 40006546 Free PMC article.
-
Optimising Seniors' Metabolism of Medications and Avoiding Adverse Drug Events Using Data on How Metabolism by Their P450 Enzymes Varies with Ancestry and Drug-Drug and Drug-Drug-Gene Interactions.J Pers Med. 2020 Aug 11;10(3):84. doi: 10.3390/jpm10030084. J Pers Med. 2020. PMID: 32796505 Free PMC article.
-
Drug-Drug-Gene Interactions in Cardiovascular Medicine.Pharmgenomics Pers Med. 2022 Nov 2;15:879-911. doi: 10.2147/PGPM.S338601. eCollection 2022. Pharmgenomics Pers Med. 2022. PMID: 36353710 Free PMC article. Review.
-
Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.Forensic Sci Med Pathol. 2011 Jun;7(2):162-84. doi: 10.1007/s12024-010-9188-3. Epub 2010 Nov 4. Forensic Sci Med Pathol. 2011. PMID: 21052868 Review.
-
Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine.Eur J Clin Pharmacol. 2010 Sep;66(9):879-87. doi: 10.1007/s00228-010-0829-y. Epub 2010 May 6. Eur J Clin Pharmacol. 2010. PMID: 20446083
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases